219716-33-3

219716-33-3 structure
219716-33-3 structure
  • Name: VisilizuMab
  • Chemical Name: VisilizuMab
  • CAS Number: 219716-33-3
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2018-06-11 09:29:19
  • Modify Date: 2024-01-03 18:00:05
  • Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1].

Name VisilizuMab
Synonyms VISILIZUMAB
Description Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1].
Related Catalog
In Vitro Visilizumab 诱导固有层 T 细胞的剂量和时间依赖性细胞凋亡。Visilizumab 诱导固有层 T 细胞凋亡依赖于半胱天冬酶 3 和 8,而不是半胱天冬酶 9 的激活,并且不涉及 Fas/FasL 通路[1]。 Apoptosis Analysis[1] Cell Line: Lamina propria T cells Concentration: 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 2 hours, 4 hours, 20 hours, 24 hours, 48 hours Result: Induced dose- and time-dependent apoptosis of lamina propria T cells.
References

[1]. Qi T Yu, et al. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9.  

No Any Chemical & Physical Properties